Patent · US Expired

Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quin azolinone

US6225317A · kind A · utility

0Cited by

1References

24Claims

0Family size

Assignee

Dupont Pharmaceuticals · US

Inventors

Shelley R. Rabel · Landenberg, US
Mona Patel · Montgomery, US
Rodney Lawrence Parsons, Jr. · Wilmington, US

Key dates

Filing date	Nov 18, 1999
Grant date	May 1, 2001
Priority date	—
Expiry date	Nov 18, 2019

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D239/78
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The potent reverse transcriptase inhibitor (-)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quin azolinone is produced in solvate and crystalline form. These forms are designated Forms 1 and 2, and are characterized by x-ray powder diffraction and differential scanning calorimetry. Pharmaceutical compositions and methods are useful for the treatment of the human immunodeficiency virus (HIV).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.